Cargando…

Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety

INTRODUCTION: The intraocular pressure (IOP)-lowering effect and safety of tafluprost 0.0015%/timolol maleate 0.5% combination ophthalmic solution (Taf–TFC) were investigated in a real-world clinical setting. METHODS: A prospective up to 2-year (more than 1 year) observational study has been initiat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takagi, Yasutaka, Osaki, Hirotaka, Yamashita, Tomohiro, Kai, Yasuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125119/ https://www.ncbi.nlm.nih.gov/pubmed/27492380 http://dx.doi.org/10.1007/s40123-016-0057-3

Ejemplares similares

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat, Lutz E, et al.
Publicado: (2017)

Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
por: Hwang, Young Hoon
Publicado: (2014)

Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study
por: Lee, Wonseok, et al.
Publicado: (2017)

Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study
por: Rolle, Teresa, et al.
Publicado: (2017)

Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
por: Schnober, Dietmar, et al.
Publicado: (2010)

Efficacy and safety of tafluprost 0.0015% – retrospective analysis of real-world data from the Philippines
por: Tumbocon, Joseph Anthony, et al.
Publicado: (2019)

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components
por: Pfeiffer, Norbert, et al.
Publicado: (2014)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
por: Hagras, Sherein M, et al.
Publicado: (2021)

Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride
por: Wong, Tina T, et al.
Publicado: (2018)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
por: Rhee, Douglas J, et al.
Publicado: (2008)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Durán, Leopoldo Martín, et al.
Publicado: (2012)

Safety of Fixed-Combination Bimatoprost 0.03%/Timolol 0.5% Ophthalmic Solution at 6 Months in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension
por: Sun, Xinghuai, et al.
Publicado: (2022)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
por: Gheith, Moataz E, et al.
Publicado: (2008)

Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin‐treated glaucoma patients
por: Aihara, Makoto, et al.
Publicado: (2017)

Fixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure
por: Lee, Anne J, et al.
Publicado: (2008)

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension
por: Lorenz, Katrin, et al.
Publicado: (2011)

Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2018)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
por: Schnober, Dietmar, et al.
Publicado: (2015)

A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma
por: Gómez-Aguayo, Francisco, et al.
Publicado: (2018)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf, Stefan, et al.
Publicado: (2016)

Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study
por: Inatani, Masaru, et al.
Publicado: (2023)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue, Kenji, et al.
Publicado: (2015)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Bell, Nicholas P, et al.
Publicado: (2010)

Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol
por: Fuwa, Masahiro, et al.
Publicado: (2019)

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products
por: Holló, Gábor, et al.
Publicado: (2014)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

The clinical effectiveness of tafluprost on Japanese normal-tension glaucoma patients
por: Nomura, Akio, et al.
Publicado: (2018)

Topical timolol 0.5% as the primary treatment of ophthalmic pyogenic granuloma: A prospective, single-arm study
por: Jaiswal, Hrishabh, et al.
Publicado: (2021)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
por: Beckers, Henny JM, et al.
Publicado: (2009)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
por: Nakamoto, Kenji, et al.
Publicado: (2018)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%
por: Gross, Ronald L, et al.
Publicado: (2007)

Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study
por: Orii, Yusuke, et al.
Publicado: (2022)

Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination
por: Fuwa, Masahiro, et al.
Publicado: (2016)

Correction to: Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

Effects of 0.5% Timolol Maleate Ophthalmic Solution on Heart Rate and Selected Echocardiographic Indices in Apparently Healthy Cats
por: Gunther‐Harrington, C.T., et al.
Publicado: (2016)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Özkurt, Yelda Buyru, et al.
Publicado: (2009)

Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma
por: Agarwal, Prerana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6sq8cjj7cj61j4hdj8uoue5d60